Latest Industry Insights
Industry Insight
Development of Immunotherapy To Treat COVID-19 in Progress
CEL-SCI Corporation recently announced that it is utilizing LEAPS peptide technology in efforts to develop an immunotherapy against the novel coronavirus caused by SARS-CoV-2. Technology Networks, spoke with Daniel Zimmerman, Ph.D. Senior VP of Research, Cellular Immunology at CEL-SCI Corporation, to learn more about the LEAPS technology.
Industry Insight
Targeting the Vaginal Microbiome for Urogenital and Reproductive Health
Technology Networks recently spoke with Dr Jacques Ravel (Chief Scientist of LUCA Biologics) and Luba Greenwood (CEO of LUCA Biologics) to learn more about what the vaginal microbiome is, how it can contribute to human pathology and the development of novel therapeutics in this space that are approaching clinical trials.
Industry Insight
Harnessing the Immune System for Early Cancer Detection
With the number of new cancer cases worldwide per year predicted to rise to 23.6 million by 2030, it seems as pertinent as ever that the disease is stopped early in its tracks. We spoke with Mike Fisher, Ph.D., Commercial Director of Oncimmune, to find out more about a trial utilizing a simple blood test for early detection of lung cancer.
Industry Insight
Exploiting Immunobiology To Treat Severe Autoimmune and Inflammatory Disorders
Technology Networks recently had the pleasure of speaking with Bruce Steel, CEO Equillium, Inc. to learn more about how they are leveraging their comprehensive understanding of immunobiology to develop novel treatments for inflammatory and autoimmune disorders.
Industry Insight
Yeast, A "Rising" Approach to Manufacturing Collagen
Technology Networks spoke with Jonathan Widdowson, Director of ProColl and Enterprise Fellow at the Royal Academy of Engineering Enterprise Hub, to learn more about how yeast can be used to manufacture collagens and the applications of this approach.
Industry Insight
A New Generation of Recombinant Monoclonal Antibodies
Technology Networks spoke with Isaku Tanida, Head of Protein and Pathway Technologies, Life Science at Merck to learn about Merck's ZooMAb® recombinant antibodies. These antibodies are developed from a B-cell immortalization technology which enables production in a variety of species.
Industry Insight
Drugging the Microbiome To Treat Obesity
Technology Networks recently spoke with Paul-Peter Tak, President & CEO, Kintai Therapeutics, to learn more about the anti-obesity agent the company is currently developing.
Industry Insight
Efforts To Sequence the Coronavirus Continue As New Gene Sequencer Is Launched in Asia
Technology Networks spoke with GenapSys to learn more about the sequencer which is "100x smaller and less expensive than legacy high-throughput sequencers" and how it can be applied to study the Coronavirus.
Industry Insight
Data from Direct-to-Consumer Genetic Tests Used To Create a Drug for Inflammatory Diseases
At the beginning of the year, direct-to-consumer (DTC) genetic testing company 23andMe announced that they have generated a bispecific antibody that blocks the IL-36 cytokine family associated with multiple inflammatory diseases. Technology Networks spoke with Christine Pai from 23andMe to find out more.
Industry Insight
An Online Educational Resource for Cell Scientists
Introduced back in March 2019, Cell MentorTM is an online educational resource for biology students and researchers, created by Cell Signaling Technology and Cell Press. To open the resource up to even more scientists, a Chinese version of the site was recently launched.
Advertisement